The role of combination medical therapy in the treatment of acromegaly

Dawn Shao Ting Lim, Maria Fleseriu

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Purpose: Uncontrolled acromegaly results in approximately 2-fold excess mortality. Pituitary surgery is first-line therapy, and medical treatment is indicated for persistent disease. While cabergoline and pegvisomant are used in select patients, somatostatin receptor ligands (SRLs) remain the cornerstone of medical treatment. Management of patients poorly responsive to SRLs is therefore, challenging. The purpose of this review is to highlight the options for combination medical therapy in the treatment of acromegaly, with an emphasis on efficacy and safety. Methods: All original articles/abstracts detailing combination medical therapy in acromegaly were identified from a PubMed search. Results: Studies reviewed included retrospective and open-label prospective studies. While the combination of SRL and cabergoline was generally well tolerated, a lower baseline insulin-like growth factor-1 (IGF-1) level was the best predictor of efficacy; this combination may be most effective in patients with mildly elevated IGF-1. SRL-pegvisomant combination normalized IGF-1 in the majority of patients; continued efficacy despite individual drug dosing reduction was also reported. The risk of significant liver enzyme elevation was, however, higher than that reported with SRL monotherapy; close monitoring is recommended. Data on pegvisomant-cabergoline combination is limited, but this may be an option in the setting of SRL intolerance. Reports on temozolomide used in combination with other medical therapies in patients with aggressive GH-secreting tumors are also summarized. Conclusion: While more prospective, randomized controlled trials on long-term efficacy and safety are needed, combination medical therapy remains a treatment strategy that should be considered for acromegaly patients poorly responsive to SRLs.

Original languageEnglish (US)
Pages (from-to)1-13
Number of pages13
JournalPituitary
DOIs
StateAccepted/In press - Aug 13 2016

Fingerprint

Acromegaly
Somatostatin Receptors
Ligands
Somatomedins
Therapeutics
temozolomide
Safety
PubMed
Randomized Controlled Trials
Prospective Studies
Mortality
Liver

Keywords

  • Acromegaly
  • Combination medical therapy
  • Dopamine agonist
  • Growth hormone receptor antagonist
  • Somatostatin receptor ligand

ASJC Scopus subject areas

  • Endocrinology, Diabetes and Metabolism
  • Endocrinology

Cite this

The role of combination medical therapy in the treatment of acromegaly. / Lim, Dawn Shao Ting; Fleseriu, Maria.

In: Pituitary, 13.08.2016, p. 1-13.

Research output: Contribution to journalArticle

@article{df6b99291f74449cade16ba33b9156f8,
title = "The role of combination medical therapy in the treatment of acromegaly",
abstract = "Purpose: Uncontrolled acromegaly results in approximately 2-fold excess mortality. Pituitary surgery is first-line therapy, and medical treatment is indicated for persistent disease. While cabergoline and pegvisomant are used in select patients, somatostatin receptor ligands (SRLs) remain the cornerstone of medical treatment. Management of patients poorly responsive to SRLs is therefore, challenging. The purpose of this review is to highlight the options for combination medical therapy in the treatment of acromegaly, with an emphasis on efficacy and safety. Methods: All original articles/abstracts detailing combination medical therapy in acromegaly were identified from a PubMed search. Results: Studies reviewed included retrospective and open-label prospective studies. While the combination of SRL and cabergoline was generally well tolerated, a lower baseline insulin-like growth factor-1 (IGF-1) level was the best predictor of efficacy; this combination may be most effective in patients with mildly elevated IGF-1. SRL-pegvisomant combination normalized IGF-1 in the majority of patients; continued efficacy despite individual drug dosing reduction was also reported. The risk of significant liver enzyme elevation was, however, higher than that reported with SRL monotherapy; close monitoring is recommended. Data on pegvisomant-cabergoline combination is limited, but this may be an option in the setting of SRL intolerance. Reports on temozolomide used in combination with other medical therapies in patients with aggressive GH-secreting tumors are also summarized. Conclusion: While more prospective, randomized controlled trials on long-term efficacy and safety are needed, combination medical therapy remains a treatment strategy that should be considered for acromegaly patients poorly responsive to SRLs.",
keywords = "Acromegaly, Combination medical therapy, Dopamine agonist, Growth hormone receptor antagonist, Somatostatin receptor ligand",
author = "Lim, {Dawn Shao Ting} and Maria Fleseriu",
year = "2016",
month = "8",
day = "13",
doi = "10.1007/s11102-016-0737-y",
language = "English (US)",
pages = "1--13",
journal = "Pituitary",
issn = "1386-341X",
publisher = "Kluwer Academic Publishers",

}

TY - JOUR

T1 - The role of combination medical therapy in the treatment of acromegaly

AU - Lim, Dawn Shao Ting

AU - Fleseriu, Maria

PY - 2016/8/13

Y1 - 2016/8/13

N2 - Purpose: Uncontrolled acromegaly results in approximately 2-fold excess mortality. Pituitary surgery is first-line therapy, and medical treatment is indicated for persistent disease. While cabergoline and pegvisomant are used in select patients, somatostatin receptor ligands (SRLs) remain the cornerstone of medical treatment. Management of patients poorly responsive to SRLs is therefore, challenging. The purpose of this review is to highlight the options for combination medical therapy in the treatment of acromegaly, with an emphasis on efficacy and safety. Methods: All original articles/abstracts detailing combination medical therapy in acromegaly were identified from a PubMed search. Results: Studies reviewed included retrospective and open-label prospective studies. While the combination of SRL and cabergoline was generally well tolerated, a lower baseline insulin-like growth factor-1 (IGF-1) level was the best predictor of efficacy; this combination may be most effective in patients with mildly elevated IGF-1. SRL-pegvisomant combination normalized IGF-1 in the majority of patients; continued efficacy despite individual drug dosing reduction was also reported. The risk of significant liver enzyme elevation was, however, higher than that reported with SRL monotherapy; close monitoring is recommended. Data on pegvisomant-cabergoline combination is limited, but this may be an option in the setting of SRL intolerance. Reports on temozolomide used in combination with other medical therapies in patients with aggressive GH-secreting tumors are also summarized. Conclusion: While more prospective, randomized controlled trials on long-term efficacy and safety are needed, combination medical therapy remains a treatment strategy that should be considered for acromegaly patients poorly responsive to SRLs.

AB - Purpose: Uncontrolled acromegaly results in approximately 2-fold excess mortality. Pituitary surgery is first-line therapy, and medical treatment is indicated for persistent disease. While cabergoline and pegvisomant are used in select patients, somatostatin receptor ligands (SRLs) remain the cornerstone of medical treatment. Management of patients poorly responsive to SRLs is therefore, challenging. The purpose of this review is to highlight the options for combination medical therapy in the treatment of acromegaly, with an emphasis on efficacy and safety. Methods: All original articles/abstracts detailing combination medical therapy in acromegaly were identified from a PubMed search. Results: Studies reviewed included retrospective and open-label prospective studies. While the combination of SRL and cabergoline was generally well tolerated, a lower baseline insulin-like growth factor-1 (IGF-1) level was the best predictor of efficacy; this combination may be most effective in patients with mildly elevated IGF-1. SRL-pegvisomant combination normalized IGF-1 in the majority of patients; continued efficacy despite individual drug dosing reduction was also reported. The risk of significant liver enzyme elevation was, however, higher than that reported with SRL monotherapy; close monitoring is recommended. Data on pegvisomant-cabergoline combination is limited, but this may be an option in the setting of SRL intolerance. Reports on temozolomide used in combination with other medical therapies in patients with aggressive GH-secreting tumors are also summarized. Conclusion: While more prospective, randomized controlled trials on long-term efficacy and safety are needed, combination medical therapy remains a treatment strategy that should be considered for acromegaly patients poorly responsive to SRLs.

KW - Acromegaly

KW - Combination medical therapy

KW - Dopamine agonist

KW - Growth hormone receptor antagonist

KW - Somatostatin receptor ligand

UR - http://www.scopus.com/inward/record.url?scp=84982105845&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84982105845&partnerID=8YFLogxK

U2 - 10.1007/s11102-016-0737-y

DO - 10.1007/s11102-016-0737-y

M3 - Article

C2 - 27522663

AN - SCOPUS:84982105845

SP - 1

EP - 13

JO - Pituitary

JF - Pituitary

SN - 1386-341X

ER -